Haleon plc
Haleon plc HLN.L Peers
See (HLN.L) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HLN.L | £405.20 | +0.47% | 36.6B | 25.32 | £0.16 | +0.02% |
| HIK.L | £2,128.00 | +1.14% | 4.7B | 17.88 | £1.19 | +2.52% |
| HCM.L | £225.00 | +0.45% | 2B | 75.00 | £0.03 | N/A |
| INDV.L | £1,015.00 | +2.68% | 1.3B | -253.75 | -£0.04 | N/A |
| 0IRF.IL | £6.98 | +0.29% | 1.2B | -12.04 | -£0.58 | N/A |
| APH.L | £64.70 | +0.02% | 349.7M | -32.35 | -£0.02 | N/A |
| AGY.L | £6.80 | -8.11% | 324.1M | -6.80 | -£0.01 | N/A |
| ANCR.L | £298.00 | -1.00% | 205.6M | 37.25 | £0.08 | +1.68% |
| BMK.L | £24.00 | -0.79% | 178M | -4.00 | -£0.06 | N/A |
| BXP.L | £38.50 | -3.04% | 171.8M | 4.28 | £0.09 | +8.70% |
Stock Comparison
HLN.L vs HIK.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, HIK.L has a market cap of 4.7B. Regarding current trading prices, HLN.L is priced at £405.20, while HIK.L trades at £2,128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas HIK.L's P/E ratio is 17.88. In terms of profitability, HLN.L's ROE is +0.09%, compared to HIK.L's ROE of +0.16%. Regarding short-term risk, HLN.L is less volatile compared to HIK.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs HCM.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, HCM.L has a market cap of 2B. Regarding current trading prices, HLN.L is priced at £405.20, while HCM.L trades at £225.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas HCM.L's P/E ratio is 75.00. In terms of profitability, HLN.L's ROE is +0.09%, compared to HCM.L's ROE of -0.01%. Regarding short-term risk, HLN.L is less volatile compared to HCM.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs INDV.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, INDV.L has a market cap of 1.3B. Regarding current trading prices, HLN.L is priced at £405.20, while INDV.L trades at £1,015.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas INDV.L's P/E ratio is -253.75. In terms of profitability, HLN.L's ROE is +0.09%, compared to INDV.L's ROE of -0.01%. Regarding short-term risk, HLN.L is less volatile compared to INDV.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs 0IRF.IL Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, 0IRF.IL has a market cap of 1.2B. Regarding current trading prices, HLN.L is priced at £405.20, while 0IRF.IL trades at £6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas 0IRF.IL's P/E ratio is -12.04. In terms of profitability, HLN.L's ROE is +0.09%, compared to 0IRF.IL's ROE of -0.22%. Regarding short-term risk, HLN.L is less volatile compared to 0IRF.IL. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs APH.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, APH.L has a market cap of 349.7M. Regarding current trading prices, HLN.L is priced at £405.20, while APH.L trades at £64.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas APH.L's P/E ratio is -32.35. In terms of profitability, HLN.L's ROE is +0.09%, compared to APH.L's ROE of -0.05%. Regarding short-term risk, HLN.L is more volatile compared to APH.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs AGY.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, AGY.L has a market cap of 324.1M. Regarding current trading prices, HLN.L is priced at £405.20, while AGY.L trades at £6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas AGY.L's P/E ratio is -6.80. In terms of profitability, HLN.L's ROE is +0.09%, compared to AGY.L's ROE of +20.72%. Regarding short-term risk, HLN.L is less volatile compared to AGY.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs ANCR.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, ANCR.L has a market cap of 205.6M. Regarding current trading prices, HLN.L is priced at £405.20, while ANCR.L trades at £298.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas ANCR.L's P/E ratio is 37.25. In terms of profitability, HLN.L's ROE is +0.09%, compared to ANCR.L's ROE of +0.31%. Regarding short-term risk, HLN.L is less volatile compared to ANCR.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs BMK.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, BMK.L has a market cap of 178M. Regarding current trading prices, HLN.L is priced at £405.20, while BMK.L trades at £24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas BMK.L's P/E ratio is -4.00. In terms of profitability, HLN.L's ROE is +0.09%, compared to BMK.L's ROE of -0.18%. Regarding short-term risk, HLN.L is more volatile compared to BMK.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs BXP.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, BXP.L has a market cap of 171.8M. Regarding current trading prices, HLN.L is priced at £405.20, while BXP.L trades at £38.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas BXP.L's P/E ratio is 4.28. In terms of profitability, HLN.L's ROE is +0.09%, compared to BXP.L's ROE of +0.13%. Regarding short-term risk, HLN.L is less volatile compared to BXP.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs 0W1Q.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, 0W1Q.L has a market cap of 81.3M. Regarding current trading prices, HLN.L is priced at £405.20, while 0W1Q.L trades at £19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas 0W1Q.L's P/E ratio is -9.08. In terms of profitability, HLN.L's ROE is +0.09%, compared to 0W1Q.L's ROE of +0.41%. Regarding short-term risk, HLN.L is less volatile compared to 0W1Q.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs VLG.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, VLG.L has a market cap of 68.5M. Regarding current trading prices, HLN.L is priced at £405.20, while VLG.L trades at £53.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas VLG.L's P/E ratio is 53.50. In terms of profitability, HLN.L's ROE is +0.09%, compared to VLG.L's ROE of +0.01%. Regarding short-term risk, HLN.L is more volatile compared to VLG.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs EAH.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, EAH.L has a market cap of 42.7M. Regarding current trading prices, HLN.L is priced at £405.20, while EAH.L trades at £63.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas EAH.L's P/E ratio is 63.00. In terms of profitability, HLN.L's ROE is +0.09%, compared to EAH.L's ROE of +0.01%. Regarding short-term risk, HLN.L is less volatile compared to EAH.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs STX.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, STX.L has a market cap of 26.8M. Regarding current trading prices, HLN.L is priced at £405.20, while STX.L trades at £2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas STX.L's P/E ratio is -1.29. In terms of profitability, HLN.L's ROE is +0.09%, compared to STX.L's ROE of +68.33%. Regarding short-term risk, HLN.L is less volatile compared to STX.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs PXS.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, PXS.L has a market cap of 13M. Regarding current trading prices, HLN.L is priced at £405.20, while PXS.L trades at £0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas PXS.L's P/E ratio is N/A. In terms of profitability, HLN.L's ROE is +0.09%, compared to PXS.L's ROE of -0.59%. Regarding short-term risk, HLN.L is less volatile compared to PXS.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs CHLL.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, CHLL.L has a market cap of 10.9M. Regarding current trading prices, HLN.L is priced at £405.20, while CHLL.L trades at £2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas CHLL.L's P/E ratio is -2.15. In terms of profitability, HLN.L's ROE is +0.09%, compared to CHLL.L's ROE of -3.55%. Regarding short-term risk, HLN.L is more volatile compared to CHLL.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs MXC.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, MXC.L has a market cap of 9.3M. Regarding current trading prices, HLN.L is priced at £405.20, while MXC.L trades at £21.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas MXC.L's P/E ratio is -0.13. In terms of profitability, HLN.L's ROE is +0.09%, compared to MXC.L's ROE of +26.60%. Regarding short-term risk, HLN.L is less volatile compared to MXC.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs CEL.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, CEL.L has a market cap of 8.9M. Regarding current trading prices, HLN.L is priced at £405.20, while CEL.L trades at £10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas CEL.L's P/E ratio is -1.25. In terms of profitability, HLN.L's ROE is +0.09%, compared to CEL.L's ROE of -1.43%. Regarding short-term risk, HLN.L is less volatile compared to CEL.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs RGT.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, RGT.L has a market cap of 4.2M. Regarding current trading prices, HLN.L is priced at £405.20, while RGT.L trades at £6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas RGT.L's P/E ratio is -0.26. In terms of profitability, HLN.L's ROE is +0.09%, compared to RGT.L's ROE of +4.20%. Regarding short-term risk, HLN.L is less volatile compared to RGT.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs N4P.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, N4P.L has a market cap of 4M. Regarding current trading prices, HLN.L is priced at £405.20, while N4P.L trades at £0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas N4P.L's P/E ratio is -0.47. In terms of profitability, HLN.L's ROE is +0.09%, compared to N4P.L's ROE of -0.91%. Regarding short-term risk, HLN.L is less volatile compared to N4P.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs HELD.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, HELD.L has a market cap of 1.4M. Regarding current trading prices, HLN.L is priced at £405.20, while HELD.L trades at £0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas HELD.L's P/E ratio is N/A. In terms of profitability, HLN.L's ROE is +0.09%, compared to HELD.L's ROE of -3.64%. Regarding short-term risk, HLN.L is more volatile compared to HELD.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs 0A4X.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, 0A4X.L has a market cap of 10. Regarding current trading prices, HLN.L is priced at £405.20, while 0A4X.L trades at £0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas 0A4X.L's P/E ratio is -0.00. In terms of profitability, HLN.L's ROE is +0.09%, compared to 0A4X.L's ROE of N/A. Regarding short-term risk, HLN.L is more volatile compared to 0A4X.L. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.L.
HLN.L vs DNL.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, DNL.L has a market cap of 0. Regarding current trading prices, HLN.L is priced at £405.20, while DNL.L trades at £27.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas DNL.L's P/E ratio is -0.03. In terms of profitability, HLN.L's ROE is +0.09%, compared to DNL.L's ROE of -0.59%. Regarding short-term risk, Volatility data is not available for a full comparison. HLN.L has daily volatility of 1.19 and DNL.L has daily volatility of N/A.
HLN.L vs AMYT.L Comparison
HLN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN.L stands at 36.6B. In comparison, AMYT.L has a market cap of 0. Regarding current trading prices, HLN.L is priced at £405.20, while AMYT.L trades at £143.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN.L currently has a P/E ratio of 25.32, whereas AMYT.L's P/E ratio is -0.04. In terms of profitability, HLN.L's ROE is +0.09%, compared to AMYT.L's ROE of -1.07%. Regarding short-term risk, HLN.L is less volatile compared to AMYT.L. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.L.